PMID- 10877213
OWN - NLM
STAT- MEDLINE
DCOM- 20000718
LR  - 20131121
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 49
IP  - 6
DP  - 2000 Jun
TI  - Regulation of hexokinase II expression in human skeletal muscle in vivo.
PG  - 814-8
AB  - The phosphorylation of glucose to glucose-6-phosphate (G-6-P) is the first 
      committed step in glucose uptake in skeletal muscle. This reaction is catalyzed 
      by hexokinase (HK). Two HK isoforms, HKI and HKII, are expressed in human 
      skeletal muscle, but only HKII is regulated by insulin. The present study was 
      undertaken to determine the time course for the regulation of HK activity and 
      expression by physiological plasma insulin concentrations in human skeletal 
      muscle in vivo. A hyperinsulinemic-euglycemic glucose clamp and percutaneous 
      muscle biopsy were performed in separate groups of healthy subjects after 60, 
      120, 180, and 360 minutes of euglycemic hyperinsulinemia. Muscle biopsies were 
      subfractionated into soluble and particulate fractions to determine HKI and HKII 
      activities. RNA was extracted from a separate portion of the muscle biopsy, and 
      HKI and HKII mRNA content was determined using an RNase protection assay. 
      Glycogen synthase (GS) activity and fractional velocity were also determined. 
      HKII mRNA was increased 2-fold by 120 minutes and remained high versus the basal 
      value for up to 360 minutes. HKI mRNA was unchanged throughout the study. HKII 
      activity increased after 360 minutes of insulin infusion, and this increase was 
      limited to the soluble fraction. In contrast, insulin induced a 1.5- to 2-fold 
      increase in GS fractional velocity that was sustained for 360 minutes. The time 
      course of the ability of hyperinsulinemia to increase HKII mRNA indicates that 
      insulin is likely a physiological regulator of HKII expression in human skeletal 
      muscle in vivo.
FAU - Vogt, C
AU  - Vogt C
AD  - Department of Medicine, The University of Texas Health Science Center, San 
      Antonio 78284-7886, USA.
FAU - Ardehali, H
AU  - Ardehali H
FAU - Iozzo, P
AU  - Iozzo P
FAU - Yki-Jarvinen, H
AU  - Yki-Jarvinen H
FAU - Koval, J
AU  - Koval J
FAU - Maezono, K
AU  - Maezono K
FAU - Pendergrass, M
AU  - Pendergrass M
FAU - Printz, R
AU  - Printz R
FAU - Granner, D
AU  - Granner D
FAU - DeFronzo, R
AU  - DeFronzo R
FAU - Mandarino, L
AU  - Mandarino L
LA  - eng
GR  - DK-24092/DK/NIDDK NIH HHS/United States
GR  - DK-46867/DK/NIDDK NIH HHS/United States
GR  - DK-47936/DK/NIDDK NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Insulin)
RN  - 0 (Isoenzymes)
RN  - 0 (RNA, Messenger)
RN  - EC 2.4.1.11 (Glycogen Synthase)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Female
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Glucose/pharmacology
MH  - Glucose Clamp Technique
MH  - Glycogen Synthase/metabolism
MH  - Hexokinase/genetics/*metabolism
MH  - Humans
MH  - Hyperinsulinism/blood/metabolism
MH  - Insulin/blood/pharmacology
MH  - Isoenzymes/metabolism
MH  - Male
MH  - Muscle, Skeletal/drug effects/*enzymology
MH  - RNA, Messenger/metabolism
MH  - Time Factors
EDAT- 2000/07/06 11:00
MHDA- 2000/07/25 11:00
CRDT- 2000/07/06 11:00
PHST- 2000/07/06 11:00 [pubmed]
PHST- 2000/07/25 11:00 [medline]
PHST- 2000/07/06 11:00 [entrez]
AID - S0026-0495(00)80073-6 [pii]
AID - 10.1053/meta.2000.6245 [doi]
PST - ppublish
SO  - Metabolism. 2000 Jun;49(6):814-8. doi: 10.1053/meta.2000.6245.